Get the Stockscreener App
2.00
4.71%
0.09
After Hours:
2.04
0.04
+2.00%
Sellas Life Sciences Group Inc stock is traded at $2.00, with a volume of 5.57M.
It is up +4.71% in the last 24 hours and up +8.11% over the past month.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
See More
Previous Close:
$1.91
Open:
$1.99
24h Volume:
5.57M
Relative Volume:
2.51
Market Cap:
$210.59M
Revenue:
-
Net Income/Loss:
$-37.34M
P/E Ratio:
-1.4706
EPS:
-1.36
Net Cash Flow:
$-36.91M
1W Performance:
+5.82%
1M Performance:
+8.11%
6M Performance:
+76.99%
1Y Performance:
+61.29%
1-Day Range:
$1.94
$2.15
1-Week Range:
$1.81
$2.15
52-Week Range:
$0.772
$2.2691
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
Name
Sellas Life Sciences Group Inc
Sector
Industry
Phone
(646) 200-5278
Address
7 TIMES SQUARE, NEW YORK, NY
Compare SLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
2.00 | 238.72M | 0 | -37.34M | -36.91M | -1.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-01-18 | Initiated | Oppenheimer | Outperform |
| Apr-02-18 | Initiated | H.C. Wainwright | Buy |
| Mar-19-18 | Upgrade | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc Stock (SLS) Latest News
Smart tools for monitoring SELLAS Life Sciences Group Inc.’s price actionEarnings Growth Report & Stepwise Swing Trade Plans - newser.com
Quantitative breakdown of SELLAS Life Sciences Group Inc. recent moveWeekly Trend Report & Low Drawdown Investment Strategies - newser.com
SELLAS Life Sciences Stock Rises On Strong Preclinical Data For Investigational Cancer Treatment - Stocktwits
What technical models suggest about SELLAS Life Sciences Group Inc.’s comebackMarket Activity Report & Real-Time Market Trend Scan - newser.com
What analyst consensus says on SELLAS Life Sciences Group Inc. stockChart Signals & Risk Managed Investment Signals - newser.com
Using R and stats models for SELLAS Life Sciences Group Inc. forecastingTrade Signal Summary & Capital Efficient Trading Techniques - newser.com
SELLAS to present CDK9 inhibitor data for T-cell leukemia at ESMO - Investing.com Australia
How SELLAS Life Sciences Group Inc. stock valuations compare to rivalsQuarterly Portfolio Summary & Weekly High Return Stock Opportunities - newser.com
How institutional ownership impacts SELLAS Life Sciences Group Inc. stockPortfolio Update Summary & Target Return Focused Stock Picks - newser.com
SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European Society for Medical Oncology (ESMO) Congress 2025 - GlobeNewswire
7.9w survival — SELLAS' SLS009 prolongs life in T-PLL vs 4.4w venetoclax; poster at ESMO Oct 18 - Stock Titan
What data driven models say about SELLAS Life Sciences Group Inc.’s futureMarket Trend Review & Weekly Momentum Stock Picks - newser.com
Using data models to predict SELLAS Life Sciences Group Inc. stock movementJuly 2025 Decliners & Precise Entry and Exit Recommendations - newser.com
How to integrate SELLAS Life Sciences Group Inc. into portfolio analysis toolsPortfolio Performance Report & High Return Trade Guides - newser.com
Published on: 2025-10-09 03:27:21 - newser.com
Published on: 2025-10-09 03:07:14 - newser.com
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Sees Significant Decrease in Short Interest - Defense World
Multi factor analysis applied to SELLAS Life Sciences Group Inc.July 2025 Momentum & Stepwise Entry/Exit Trade Alerts - newser.com
Using Python tools to backtest SELLAS Life Sciences Group Inc. strategies2025 Dividend Review & Free Accurate Trade Setup Notifications - newser.com
Can SELLAS Life Sciences Group Inc. (RXK3) stock double in coming years2025 Short Interest & Stock Market Timing Techniques - newser.com
Published on: 2025-10-06 05:59:31 - newser.com
SELLAS Extends Times Square Sublease Agreement - TipRanks
Why SELLAS Life Sciences Group Inc. (RXK3) stock benefits from AI revolutionEarnings Risk Summary & Community Consensus Picks - newser.com
Published on: 2025-10-03 03:10:59 - newser.com
Chart based analysis of SELLAS Life Sciences Group Inc. trendsJuly 2025 Patterns & Weekly Top Gainers Trade List - newser.com
Is SELLAS Life Sciences Group Inc. stock bottoming out2025 Buyback Activity & Daily Profit Focused Screening - newser.com
Published on: 2025-10-02 22:11:46 - newser.com
Will SELLAS Life Sciences Group Inc. (RXK3) stock test record highs in 20252025 Volume Leaders & High Conviction Investment Ideas - newser.com
SELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 Program Update - Sahm
SELLAS Life Sciences to host virtual R&D day on AML treatments - Investing.com Nigeria
How Product Roadmap Could Affect Music Broadcast Limiteds Future ValueResistance Zone Identification & Free Stock Education Platform for New Investors - earlytimes.in
SELLAS Life Sciences to host virtual R&D day on AML treatments By Investing.com - Investing.com South Africa
What drives SELLAS Life Sciences Group Inc RXK3 stock priceHigh Beta Stocks & Fast Growing Investment Plans - earlytimes.in
SELLAS Life Sciences Group to Host Virtual R&D Day on - GlobeNewswire
Major AML Treatment Updates: SELLAS Life Sciences to Reveal Phase 3 REGAL Results & New Drug Progress - Stock Titan
Published on: 2025-09-30 01:16:34 - newser.com
What high frequency data says about SELLAS Life Sciences Group Inc.Market Activity Recap & Weekly Momentum Picks - newser.com
Published on: 2025-09-29 11:38:19 - newser.com
Published on: 2025-09-29 09:42:54 - newser.com
Sellas Life Sciences Group Inc Stock (SLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sellas Life Sciences Group Inc Stock (SLS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Wasman Jane | Director |
May 30 '25 |
Buy |
1.69 |
20,000 |
33,800 |
30,400 |
| Kalin Katherine Bach | Director |
May 22 '25 |
Buy |
1.80 |
20,000 |
36,000 |
41,000 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):